Blood exosomal RNA test to diagnose clinically significant prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, multi-center study collecting blood from men suspected of having prostate cancer to measure a plasma exosome RNA signature. Participants will generally have elevated PSA or suspicious findings on exam or imaging and must be willing to undergo prostate biopsy. Researchers will compare the RNA signature results to biopsy outcomes to determine how well the blood test identifies clinically significant cancer. No investigational treatments are given; the study uses blood samples and standard diagnostic procedures across participating hospitals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Blood prostate-specific antigen PSA\>4ng/dl;
2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
3. The patient is willing to undergo prostate biopsy.

Exclusion Criteria:

1. Previous diagnosis of prostate cancer through prostate biopsy;
2. History of other malignant tumors in the past two years;
3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment

Where it's running

• Northwestern Memorial Hospital
  Chicago, Illinois, United States Recruiting
• The First Hospital of Lanzhou University
  Lanzhou, Gansu, China Recruiting
• General Hospital of Ningxia Medical University
  Yinchuan, Ningxia, China Recruiting
• Qinghai University Affiliated Hospital
  Xining, Qinghai, China Recruiting
• Weinan Central Hospital
  Weinan, Shaanxi, China Recruiting
• Shaanxi Provincial People's Hospital
  Xi'an, Shaanxi, China Recruiting

Study contacts

• Study coordinator: Jianhua Jiao, MD.
• Email: 1531769428@qq.com
• Phone: +86 029 84771062

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Transperineal vs Transrectal Cognitive Fusion Biopsy for Prostate Cancer

  This study tests whether a transperineal cognitive fusion biopsy works as well as the traditional transrectal approach for detecting clinically significant prostate cancer in men with suspicious mpMRI findings.

  Recruiting Ankara Etlik City Hospital · Ankara, Yenimahalle · NCT07710807

• Multi-Modal Imaging and Digital Pathology to Predict Clinically Significant Prostate Cancer

  A multi-center study tests a deep learning model that combines MRI, ultrasound, and digital pathology to see if it can predict clinically significant prostate cancer non-invasively and help guide biopsies.

  Recruiting Guangxi Medical University · Liuzhou, Guangxi · NCT07614256

• Using PSMA PET/CT imaging to help choose which men with low-risk prostate cancer can enter active surveillance

  The team will test whether delayed Ga-68 PSMA PET/CT scans using the Istanbul PSMA PET/CT Criteria can help decide which men with biopsy-confirmed low-risk prostate cancer can safely choose active surveillance.

  Recruiting at 10 sites Istanbul University - Cerrahpasa · Istanbul, Turkey and 9 other locations · NCT07168616

• Lowering portal pressure before liver transplant to reduce bleeding

  We will test if lowering portal pressure with a TIPS procedure or with non-selective beta-blocker medication before liver transplant can reduce blood loss for adults with cirrhosis and clinically significant portal hypertension who are at higher risk of heavy bleeding.

  Recruiting Medical University of Warsaw · Warsaw · NCT07111221

• Understanding prostate cancer through urine analysis

  This study is testing if analyzing urine can help identify important signs of prostate cancer in men and women who are having or just had a prostate biopsy.

  Recruiting National Taiwan University Hospital · Taipei · NCT03237702

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.